Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: alpha-Clopenthixol dihydrochloride
RN: 633-59-0
UNII: R3BMY435Z0
InChIKey: LPWNZMIBFHMYMX-MHKBYHAFSA-N

Note

  • A thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.

Molecular Formula

  • C22-H25-Cl-N2-O-S.2Cl-H

Molecular Weight

  • 473.8933
 

Classification Code

  • Drug / Therapeutic Agent
* denotes mobile formatted website

Links to Resources


Search for this InChIKey on the Web

Names and Synonyms

Results Name

  • alpha-Clopenthixol dihydrochloride

Name of Substance

  • Clopenthixol hydrochloride

Synonyms

  • 4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol dihydrochloride
  • AY 62021
  • Chlorpenthixol dihydrochloride
  • Chlorperphenthixene dihydrochloride
  • Ciatyl
  • Clopenthixol dihydrochloride
  • Clopenthixol HCl
  • EINECS 211-194-3
  • FDA 0199
  • N 746
  • N-746
  • NSC 169185
  • NSC 78203
  • Sordenac
  • UNII-R3BMY435Z0
  • W 2304

Systematic Names

  • 1-Piperazineethanol, 4-(3-(2-chloro-9H-thioxanthen-9-ylidene)propyl)-, dihydrochloride (9CI)
  • 1-Piperazineethanol, 4-(3-(2-chlorothioxanthen-9-ylidene)propyl)-, dihydrochloride
  • 4-(3-(2-Chloro-9H-thioxanthen-9-ylidene)propyl)piperazine-1-ethanol dihydrochloride

Registry Numbers

CAS Registry Number

  • 633-59-0

FDA UNII

  • R3BMY435Z0

System Generated Number

  • 0000633590

Molecular Formulas

Molecular Formula

  • C22-H25-Cl-N2-O-S.2Cl-H

Molecular Formula Fragments

  • C22-H25-Cl-N2-O-S
  • Cl-H
  • COMPONENT

Structure Descriptors

InChI

1S/C22H25ClN2OS.2ClH/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26;;/h1-2,4-8,16,26H,3,9-15H2;2*1H/b18-5-;;

InChIKey

LPWNZMIBFHMYMX-MHKBYHAFSA-N

Smiles

c1ccc2c(c1)/C(=C/CCN3CCN(CC3)CCO)/c4cc(ccc4S2)Cl.Cl.Cl

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
mouse LD50 intraperitoneal 222mg/kg (222mg/kg)   "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 67, 1972.
mouse LD50 intravenous 111mg/kg (111mg/kg)   United States Patent Document. Vol. #3996211,
mouse LD50 oral 560mg/kg (560mg/kg)   "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 67, 1972.
rat LD50 intraperitoneal 105mg/kg (105mg/kg)   "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 67, 1972.
rat LD50 intravenous 125mg/kg (125mg/kg)   "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 67, 1972.
rat LD50 oral 660mg/kg (660mg/kg)   "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 67, 1972.